US4784857A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Drug delivery device, its preparation and use
Assignee: Smith and Nephew PLC
•
Filing: 1987-06-02
•
Granted: 1988-11-15
•
Expires: 2007-06-02
Abstract
Abstract A device suitable for the topical administration of a pharmacologically active agent to an animal is described. The device comprises an active agent impermeable barrier layer, a reservoir containing the active agent which is in contact with the inner surface of the barrier layer and a removable protector layer in contact with the other surface of the reservoir. The reservoir comprises a fibrous mat into which the pharmacologically active agent is incorporated either by dissolving in the polymer forming the mat or by impregnation of a preformed mat. Alternative forms of the reservoir comprise a fibre mat coated on a skin contacting surface with a pressure sensitive adhesive and a fibre mat contained within a gel matrix. The device may be used to deliver nitroglycerin, oxybutynin or phenazocine transdermally.
Inventors
- 👤 Peter W. Berry
- 👤 Paul Holden
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 13:27
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
59 words
A device suitable for the topical administration of a pharmacologically active agent comprising an active agent impermeable barrier layer, a reservoir comprising a thermoplastic polyurethane fibre mat containing the pharmacologically active agent having one surface in contact with the inner surface of the barrier layer and a protector layer removably in contact with the other surface of the reservoir.
Claim 2
Independent Claim
59 words
A device suitable for the topical administration of a pharmacologically active agent comprising an active agent impermeable barrier layer, a reservoir comprising a thermoplastic polyurethane fibre mat containing the pharmacologically active agent having one surface in contact with the inner surface of the barrier layer and a protector layer removably in contact with the other surface of the reservoir.
Claim 3
Dependent Claim
31 words
A device according to claim 1 in which the fibre mat is formed from fibres of a hydrophilic polyurethane which contains from 10 to 50% by weight of water when hydrated.
Claim 4
Dependent Claim
23 words
A device according to claim 1 in which the weight per unit area of the fibre mat is from 150 to 250 gsm.
Claim 5
Dependent Claim
28 words
A device according to claim 1 in which the reservoir comprises a fibre mat coated on its body contacting surface with a layer of a pressure sensitive adhesive.
Claim 6
Dependent Claim
22 words
A device according to claim 4 in which the adhesive is present at a weight per unit area of below 25 gsm.
Claim 7
Dependent Claim
15 words
A device according to claim 4 in which the adhesive is polyvinyl ethyl ether adhesive.
Claim 8
Dependent Claim
27 words
A device according to claim 1 in which the reservoir comprises a fibre mat supported in a polymer matrix which is permeable to the pharmacologically active agent.
Claim 9
Dependent Claim
14 words
A device according to claim 7 in which the polymer matrix is silicone gel.
Claim 10
Dependent Claim
32 words
A device according to claim 1 in which the impermeable device layer has an area which extends beyond the reservoir around its periphery and is adhesive coated for adhesion to the skin.
Claim 11
Dependent Claim
29 words
A device according to claim 1 in which there is additionally present an adhesive coated cover layer which covers and extends beyond the periphery of the impermeable barrier layer.
Claim 12
Dependent Claim
23 words
A device according to claim 1 in which the barrier layer comprises a backing film coated on its inner surface with an adhesive.
Claim 13
Dependent Claim
33 words
A device according to claim 1 in which the pharmacologically active agent is selected from the group consisting of nitroglycerin, cloridine, scopolamine, isosorbide dinitrate, pentaerythritol tetranitrate, estradiol, indomethacine, verapamil, propranolol, oxybutynin and phenazocine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-15 | 1992-05-16 | 1992-11-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-15 | 1996-05-16 | 1996-11-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-15 | 2000-05-16 | 2000-11-15 | $7700.00 | Window Closed / Lapsed |